<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473148</url>
  </required_header>
  <id_info>
    <org_study_id>P051018</org_study_id>
    <nct_id>NCT00473148</nct_id>
  </id_info>
  <brief_title>B-type Natriuretic Peptide for the Management of Weaning</brief_title>
  <acronym>BMW</acronym>
  <official_title>Weaning of Mechanical Ventilation Guided by the Natriuretic Peptide of Type B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dräger Médical S.A</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biosite</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several clinical findings and clinical trials have suggested that the prognosis of intensive&#xD;
      care unit (ICU) patients may be improved by minimizing the positive fluid balance. In&#xD;
      particular, a global vascular overload could lead to weaning failure. The purpose of this&#xD;
      international, multicenter, controlled, randomized trial is to test if the incorporation of a&#xD;
      B-type natriuretic peptide (BNP) assay in a mechanical ventilation weaning protocol helps&#xD;
      optimize the weaning process and reduce the duration of the ventilatory weaning period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mechanical ventilation may give rise to complications with an incidence that increases with&#xD;
      the duration of respiratory support. The purpose of the weaning procedure is to reduce the&#xD;
      duration of mechanical ventilation without incurring a substantial risk of failure. Several&#xD;
      clinical findings and clinical trials have suggested that the prognosis of ICU patients may&#xD;
      be improved by minimizing the positive fluid balance. In particular, a global vascular&#xD;
      overload could lead to weaning failure. B-type natriuretic peptide (BNP) is a hormone&#xD;
      secreted by the ventricular cardiomyocytes in response to increased wall stretch, and its&#xD;
      plasma levels are correlated with left ventricular filling pressure. In a preliminary study&#xD;
      on 102 patients undergoing weaning from mechanical ventilation, the baseline BNP levels&#xD;
      before weaning were found to be an independent risk factor for weaning failure. In surviving&#xD;
      patients, BNP levels were significantly correlated with the duration of weaning procedure.&#xD;
      The purpose of this international, multicenter, controlled, randomized trial is to test if&#xD;
      the incorporation of a BNP assay in a mechanical ventilation weaning protocol helps optimize&#xD;
      the weaning process and reduce the duration of ventilatory weaning period. Patients on&#xD;
      mechanical ventilation presenting weaning criteria will be randomly assigned to two groups&#xD;
      (standard physician-directed weaning or weaning guided by BNP assay). In order to standardize&#xD;
      the weaning process, patients will be ventilated with an automatic computer-driven weaning&#xD;
      system in the two groups (EVITA Smart Care System, Drager Medical). A blood sample will be&#xD;
      collected from all patients every morning for BNP assay by the rapid immunofluorescence test&#xD;
      (Triage BNP Test, BIOSITE). In the control group, the clinician will not be informed about&#xD;
      the assay results and weaning will be carried out according to usual practices. Patients in&#xD;
      the intervention group will receive diuretics according to a clinical practice algorithm&#xD;
      based on plasma BNP levels and a fluid intake restriction. The primary endpoint for the two&#xD;
      groups will be duration of weaning from mechanical ventilation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of weaning from invasive ventilation</measure>
    <time_frame>during ventilation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total duration of weaning from invasive and noninvasive ventilation</measure>
    <time_frame>during hospitalisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of mechanical ventilation</measure>
    <time_frame>during hospitalisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the ICU, length of stay in hospital, number of complications in intensive care, number of prolonged weanings (&gt; 15 days), number of cases of nosocomial pneumonia, number of successful extubations, extubation complication rates</measure>
    <time_frame>during hospitalisation in ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of stay in the ICU</measure>
    <time_frame>in the ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of stay in hospital</measure>
    <time_frame>during the all stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in ICU</measure>
    <time_frame>in ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality sixty days after randomization</measure>
    <time_frame>sixty days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">265</enrollment>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BNP-guided treatment (Furosemide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BNP-guided weaning</intervention_name>
    <description>BNP-guided weaning</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard physician-directed weaning</intervention_name>
    <description>Standard physician-directed weaning</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Intubated patient receiving mechanical ventilation for at least 24 hours&#xD;
&#xD;
          -  SpO2 ≥ 90% with FiO2 ≤ 50% and PEP ≤ 8 cm H2O&#xD;
&#xD;
          -  Hemodynamic stability without vasopressor therapy (dopamine ≤ 10 γ/kg/min and&#xD;
             dobutamine ≤ 10 γ/kg/min are however allowed) nor fluid bolus (rapid infusion of at&#xD;
             least 500 ml of macromolecules or 1000 ml of saline) during the twelve previous hours&#xD;
&#xD;
          -  Sedation stopped or reduced during the previous 48 hours (analgesia may be continued)&#xD;
&#xD;
          -  Stable neurological status with Ramsay score ≤ 5&#xD;
&#xD;
          -  Body temperature &gt; 36.0 °C and &lt; 39 °C&#xD;
&#xD;
          -  Informed consent signed by patient or close relative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        I: Definite exclusion criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Known allergy to furosemide or sulphonamides&#xD;
&#xD;
          -  Tracheotomy on inclusion&#xD;
&#xD;
          -  Hepatic encephalopathy&#xD;
&#xD;
          -  Cerebral edema, acute hydrocephaly&#xD;
&#xD;
          -  Myasthenia gravis or acute idiopathic polyradiculoneuritis (Guillain-Barré syndrome)&#xD;
&#xD;
          -  Decision to withdraw life support&#xD;
&#xD;
          -  Prolonged cardiac arrest with poor neurological prognosis&#xD;
&#xD;
        II: Temporary exclusion criteria:&#xD;
&#xD;
          -  Extubation of the patient programmed for the same day&#xD;
&#xD;
          -  Acute right ventricular insufficiency (pulmonary embolism, right myocardial&#xD;
             infarction)&#xD;
&#xD;
          -  Renal insufficiency defined by one of the following: renal replacement therapy, or&#xD;
             plasma urea &gt; 25 mmol/L, or plasma creatinine &gt; 180 µmol/L, or creatinine clearance &lt;&#xD;
             30 mL/min or increase by more than 25% of plasma creatinine during the previous 24&#xD;
             hours&#xD;
&#xD;
          -  One of the following metabolic abnormalities: blood sodium &gt; 150 mEq/L; blood&#xD;
             potassium &lt; 3.5 mEq/L; metabolic alkalosis with arterial pH &gt; 7.50&#xD;
&#xD;
          -  Injection of iodinated contrast agent during the preceding six hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armand Mekonto Dessap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>May 11, 2007</study_first_submitted>
  <study_first_submitted_qc>May 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <last_update_submitted>April 29, 2010</last_update_submitted>
  <last_update_submitted_qc>April 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christophe AUCAN: Manager</name_title>
    <organization>Department of Clinical Research and Development</organization>
  </responsible_party>
  <keyword>Duration of weaning from invasive ventilation</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Weaning</keyword>
  <keyword>B-type natriuretic peptide</keyword>
  <keyword>Fluid balance</keyword>
  <keyword>Diuretics</keyword>
  <keyword>Intubated patient receiving mechanical ventilation</keyword>
  <keyword>for at least 24 hours</keyword>
  <keyword>Respiratory insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

